Dublin / Buffalo / Houston / Raleigh / New York / Nashville / Toronto / Chicago / /
Company
1International Working Group / Astex Pharmaceuticals Inc. / Johnson and Johnson / Celgene / Incyte / SU2C SGI / /
Event
FDA Phase / /
Facility
Temple University / Princess Margaret Cancer Center / Mohammad Azab14 University of Texas / Sarah Cannon Research Institute / Roswell Park Cancer Institute / Weill Cornell Medical College / University of Chicago Medical Center / MD Fels Institute / Mayo Clinic / University of Southern California / MD Anderson Cancer Center / The Ohio State University / Duke University Medical Center / Temple University On Behalf / Fels Institute / /
Sarah Cannon Research Institute / Princess Margaret Cancer Center / Temple University On Behalf of the SGI-110 Investigative Team Hagop Kantarjian1 / University of Southern California / Los Angeles / Yale University School of Medicine / The Ohio State University / Columbus / USC Keck School of Medicine / American Society of Hematology / Fels Institute / Temple University / Philadelphia / 55th Annual Meeting and Exposition American Society / Weill Cornell Medical College / Duke University Medical Center / Roswell Park Cancer Institute / University of Texas / University of Chicago Medical Center / /
Person
Yong Hao / George Dimitrov / Karen Yee / Thomas Ervin / Jean Pierre Issa / Gail Roboz / Farhad Ranvandi / Mohammad Azab / Raoul Tibes / Michael Savona / Jorge Cortes / Wendy Stock / Guillermo GarciaManero / Sue Naim / Eric Feldman / Joseph Brandwein / Katherine Walsh / Patricia Kropf / Elizabeth Griffiths / Nikola Podoltsev / William Wierda / Gavin Choy / Gautam Borthakur / Englewood / Elias Jabbour / David Rizzieri / /
Position
Cancer Specialist / Major / /
Product
SQ injection / SGI-110 / /
ProvinceOrState
Texas / Southern California / New York / Arizona / /
First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML) Jean Pierre Issa, MD Fels Institute, Temple Univ